ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EWTX
LEGN (60) INDV (51) LQDA (36) ARQT (54) ⌘ Pro Terminal →

Edgewise Therapeutics Inc. (EWTX) — RQD Stock Rating Cockpit

$38.11 -2.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $37.90

Edgewise Therapeutics Inc. (EWTX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $4.22B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EWTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EWTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Edgewise Therapeutics Inc. (NASDAQ: EWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $38.11 (-2.03% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EWTX compare to LEGN and INDV in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EWTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.9%. By comparison, LEGN (Legend Biotech Corporation) holds a C- grade (60/100 RQD, P/E 32.8x, ROIC 9.9%, cap $4.21B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EWTX?
▼

Per EWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710072), Edgewise Therapeutics Inc. generated $535.9M in revenue (+20.5% YoY), -$167.8K in net income, and -$144.1M in free cash flow against $552.6M in total assets and $13.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $37.90 (-0.56%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (5)Whales (10)SEC (13)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$51 Bull$35 Base$27 Bear
📬 FREE EWTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EWTX)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY EWTX SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)

20D Institutional Volume Accumulation (±9.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$37.02+7.1% Next Q
Q2 (-2Q)
36
Grade E$39.65+2.1% Next Q
Q3 (-1Q)
38
Grade E$40.49-5.9% Next Q
Current
41
Grade D-$38.11-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EWTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EWTX currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($41.01) and Max Pain ($40.02) forces dealer call-delta covering toward $50.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EWTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EWTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
45.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE67% OF RANGE
L: $17$38.11H: $49
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on EWTX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-31.9% ROIC with 42.0% gross margin and -3.41% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 26.00 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (38)

13/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like EWTX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EWTX)

  • ✓Walkthrough of EWTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EWTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.18%📐 HORIZONTAL RANGE
2026-11-03O $38.91H $38.91L $38.11C $38.11VOL 967.6K
RES: $51.43SUP: $35.24SMA50: $41.01SMA200: $36.45
$50.32$42.83$35.34$27.85$20.36RES $51.43SUP $35.24$38.112026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EWTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EWTX Butterfly Map → + Track EWTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
18.7%/yr Implied 5Y Growth

vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EWTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EWTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EWTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EWTX)

Health Care Rank #433 of 1015 ⚔️ LEGN vs EWTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EWTX vs. LEGN, INDV, LQDA, ARQT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Edgewise Therapeutics Inc. (EWTX) ranks #433 by composite RQD confidence (41/100, grade D-) and #173 by equity capitalization ($4.22B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with EWTX at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EWTX ACTIVE
Edgewise Therapeutics Inc.
D- 41/100 — — -31.9% -2.03% $4.22B Benchmark Subject
LEGN
Legend Biotech Corporation
C- 60/100 32.8x — 9.9% -2.45% $4.21B /legn-vs-ewtx →
INDV
Indivior Pharmaceuticals Inc.
D 51/100 19.8x 80.2% 62.2% +0.34% $4.17B /indv-vs-ewtx →
LQDA
Liquidia Corporation
D- 36/100 — — -12.6% -7.12% $4.03B /lqda-vs-ewtx →
ARQT
Arcutis Biotherapeutics Inc.
D+ 54/100 — 90.2% -3.0% -2.53% $4.03B /arqt-vs-ewtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001710072 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Edgewise Therapeutics Inc. (EWTX) reported GAAP revenue of $535.9M (+20.5% vs. FY2024 revenue of $444.7M , and +67.4% cumulative change since FY2023) , GAAP net income of -$167.8K, operating cash flow of -$143.8M, and free cash flow of -$144.1M (-30.6% YoY). On the balance sheet, EWTX closed FY2025 with $552.6M in total assets against $13.7M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $535.9M -$167.8K -$143.8M -$144.1M $552.6M $13.7M
FY2024 (FY) 2024-12-31 $444.7M -$133.8K -$109.0M -$110.3M $486.8M $12.4M
FY2023 (FY) 2023-12-31 $320.2M -$100.2K -$91.9M -$91.9M $2.32B $543.9M

3. EWTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EWTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Edgewise Therapeutics Inc. (NASDAQ: EWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $38.11 (-2.03% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does EWTX compare to LEGN and INDV in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EWTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.9%. By comparison, LEGN (Legend Biotech Corporation) holds a C- grade (60/100 RQD, P/E 32.8x, ROIC 9.9%, cap $4.21B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EWTX?

Per EWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710072), Edgewise Therapeutics Inc. generated $535.9M in revenue (+20.5% YoY), -$167.8K in net income, and -$144.1M in free cash flow against $552.6M in total assets and $13.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EWTX trading relative to its 50-day, 200-day, and 52-week technical levels?

EWTX last traded at $38.11 (-2.03% on volume of 1,083,640 shares), positioning the stock -7.07% below its 50-day simple moving average ($41.01) and +4.55% above its 200-day simple moving average ($36.45). Across its 52-week range of $16.70 to $48.51, EWTX sits at the 67.3% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($34.49 to $41.73).

Direct Sub-Reports: EWTX RQD Cockpit EWTX 12M Forecast EWTX Earnings & Move EWTX Dividends & DRIP EWTX Insiders & 13F EWTX Whale Options EWTX Profit Sankey EWTX News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

EWTX — Edgewise Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Edgewise Therapeutics Inc. (EWTX) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $38.11 (-2.03% 1D, market capitalization $4.22B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -31.9%, gross margin of —, operating margin of -16.2%, and free cash flow yield of -3.41%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.10x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 3/9, and Debt/Equity of 0.02x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Edgewise Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, so the company currently reports no commercial revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Edgewise Therapeutics Inc. (EWTX) reported $535.9M in annual revenue (up from $444.7M in FY2024, +20.5% YoY) and -$167.8K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($320.2M revenue, -$100.2K net income) through FY2025, EWTX scaled operating cash flow to -$143.8M and free cash flow to -$144.1M, backed by $552.6M in total assets against $13.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.41% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $16.70 – $48.51 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -16.2% operating margins and a 1.10x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The one quantified sector-level linkage is the liquidity sensitivity described above: a 2.21x beta to net liquidity means funding conditions and risk appetite for long-duration biotech equities are the main 2nd-order transmission channel. Watch for any deterioration in high-yield spreads or a continued decline in net liquidity, as either would amplify pressure on a company with negative free cash flow.

  • Key Question #1: Can EWTX sustain or expand its -16.2% operating margin and -31.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $535.9M and free cash flow of -$144.1M, how will capital allocation balance growth reinvestment against $13.7M in total debt?
  • Key Question #3: How sensitive is EWTX's 25.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.10x)?

EWTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Edgewise Therapeutics Inc. (EWTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EWTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EWTX Bull vs. Bear Conversation Board — What's Your Call at $38.11?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EWTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EWTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $48.62 (+25.0%)
📌 Pinned Debate

Low leverage (Debt/Equity 0.02) and a 25 forward P/E on a Phase 3 hypertrophic cardiomyopathy program with continued buy ratings from R

Don't sleep on EWTX's setup in Health Care. Low leverage (Debt/Equity 0.02) and a 25 forward P/E on a Phase 3 hypertrophic cardiomyopathy program with continued buy ratings from RBC and H.C. Wainwright.. Beta of 1.1 means it moves fast when momentum turns, and the 5-pillar RQD gauge (41/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@FadeTheHype Fair point on 25.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $30.34 (-22.0%)
Spot @ $38.90

Negative free cash flow in every reported period, ROIC of -31.9%, and a 2.21x liquidity beta leave the stock exposed if funding conditi

Here is the bear case nobody on the bull side wants to address on EWTX: Negative free cash flow in every reported period, ROIC of -31.9%, and a 2.21x liquidity beta leave the stock exposed if funding conditions tighten.. At 25.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%